Automated mood disorder symptoms monitoring from multivariate time-series sensory data: getting the full picture beyond a single number
- PMID: 38531865
- PMCID: PMC10965916
- DOI: 10.1038/s41398-024-02876-1
Automated mood disorder symptoms monitoring from multivariate time-series sensory data: getting the full picture beyond a single number
Abstract
Mood disorders (MDs) are among the leading causes of disease burden worldwide. Limited specialized care availability remains a major bottleneck thus hindering pre-emptive interventions. MDs manifest with changes in mood, sleep, and motor activity, observable in ecological physiological recordings thanks to recent advances in wearable technology. Therefore, near-continuous and passive collection of physiological data from wearables in daily life, analyzable with machine learning (ML), could mitigate this problem, bringing MDs monitoring outside the clinician's office. Previous works predict a single label, either the disease state or a psychometric scale total score. However, clinical practice suggests that the same label may underlie different symptom profiles, requiring specific treatments. Here we bridge this gap by proposing a new task: inferring all items in HDRS and YMRS, the two most widely used standardized scales for assessing MDs symptoms, using physiological data from wearables. To that end, we develop a deep learning pipeline to score the symptoms of a large cohort of MD patients and show that agreement between predictions and assessments by an expert clinician is clinically significant (quadratic Cohen's κ and macro-average F1 score both of 0.609). While doing so, we investigate several solutions to the ML challenges associated with this task, including multi-task learning, class imbalance, ordinal target variables, and subject-invariant representations. Lastly, we illustrate the importance of testing on out-of-distribution samples.
© 2024. The Author(s).
Conflict of interest statement
All authors report no financial or other relationship relevant to the subject of this article. GA has received CME-related honoraria, or consulting fees from Angelini, Casen Recordati, Janssen-Cilag, Lundbeck, Lundbeck/Otsuka, and Rovi, with no financial or other relationship relevant to the subject of this article. IP has received CME-related honoraria, or consulting fees from Janssen-Cilag, Lundbeck, Lundbeck/Otsuka, CASEN Recordati and Angelini, with no financial or other relationship relevant to the subject of this article. MV has received research grants from Eli Lilly & Company and has served as a speaker for Abbott, Bristol–Myers Squibb, GlaxoSmithKline, Janssen–Cilag, and Lundbeck. MG has received CME-related honoraria, or consulting fees from Angelini, Janssen-Cilag, Lundbeck, Lundbeck/Otsuka, and Ferrer, with no financial or other relationship relevant to the subject of this article. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, Medincell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatris, outside the submitted work. DHM has received CME-related honoraria and served as consultant for Abbott, Angelini, Ethypharm Digital Therapy and Janssen-Cilag.
Figures



References
-
- American Psychiatric Association D, Association AP, others Diagnostic and statistical manual of mental disorders: DSM-5. American psychiatric association Washington, DC, 2013
-
- Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, et al. Bipolar disorders. Nat Rev Dis Prim. 2018;4:16. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous